Sarah McDonald, cancer survivor and author of The Cancer Channel, discusses her experience battling 2 different unrelated cancers and the value oncology pharmacists could have provided with a greater presence on her care team. Watch FDA Grants Accelerated Approval to Tucatinib Combination for Patients ...
We have demonstrated for the first time that suppression of miRNA-221/222 increases the sensitivity of ER-positive MCF-7 breast cancer cells to tamoxifen. This effect is mediated through upregulation of TIMP3. These findings suggest that upregulation of TIMP3 via inhibition of miRNA-221/222 ...
I’m not sure [exactly] when HER2-positive trials are going to read out, but several studies are ongoing in the curative setting, looking at, for example, the use of tucatinib [Tukysa] in the curative setting; T-DXd in the frontline setting of metastatic breast cancer...
This retrospective mediation analysis examines the proportion of the Black-White disparity in breast cancer survival from estrogen receptor–positive,
Breast cancer (BRCA) has a high incidence and mortality rate among women. Different molecular subtypes of breast cancer have different prognoses and require personalized therapies. It is imperative to find novel therapeutic targets for different molecular subtypes of BRCA. Here, we demonstrated for the...
There is little evidence that dietary supplements are beneficial for patients with breast cancer; therefore, they are usually not recommended by treatment guidelines. The aim of the present analysis was to assess the prevalence of dietary supplement (DS) intake among women before and after a breast...
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2019. 4. Nelson HD, Fu R, Zakher B, et al. Medication use for the risk reduction of prima...
AstraZeneca and Daiichi Sankyo have received the US FDA priority review for the application of breast cancer drug, trastuzumab deruxtecan.
Bone metastases occur in 50–70% of patients with late-stage breast cancers and effective therapies are needed. The expression of enhancer of zeste homolog 2 (EZH2) is correlated with breast cancer metastasis, but its function in bone metastasis hasn’t
The interplay of positive and negative interactions between drug-sensitive and resistant cells influences the effectiveness of treatment in heterogeneous cancer cell populations. Here, we study interactions between estrogen receptor-positive breast cancer cell lineages that are sensitive and resistant to ribo...